← Back

Theon International Plc

Theon International Plc develops and manufactures customizable night vision, thermal imaging, and electro-optical ISR systems for military and security applications in Europe and internationally. Its products include monoculars, binoculars, weapon sights, clip-on devices, platform-based imaging systems, fused and augmented reality devices, ISR optronics, border and coastal surveillance EO systems, and vehicle driver viewers/cameras. The company also provides spare and repair parts, logistics support, test article refurbishment, and warranty and maintenance services. Founded in 1997, it is headquartered in Nicosia, Cyprus, and operates as a subsidiary of Venetus Limited.

Price · split & dividend adjusted
News & notes moving THEON.AS
Greece
THEON.AS▲

THEON International Publishes H1 2026 Report, Secures €325m Financing

THEON International PLC has published its H1 2026 Report for the six months ended 30 June 2026, reiterating strong revenue growth of 35.4% and an Adjusted EBIT margin of 26.2%. The company also secured a syndicated financing facility of €325 million coordinated by Alpha Bank, strengthening its liquidity and funding flexibility. CEO Christian Hadjiminas highlighted the expansion of the addressable market to nearly €8 billion through acquisitions and partnerships. The report is available on the IR website, and a live webcast for analysts and investors is scheduled for tomorrow at 3:00 PM EEST.
THEON.AS · Capital · Positive Secured €325m financing and reported strong H1 2026 results with 35.4% revenue growth and 26.2% EBIT margin.
Read original ↗
Bloomberg·27dRead more →
Defense & Geopolitical Fragmentation▲impact 4

THEON receives new orders of about €70 million and continues strategic acceleration

THEON International Plc announced total new order intake of approximately €70 million, with a significant portion coming from Rheinmetall for the Bundeswehr's Future Soldier program, including a new firm order and exercised options for products from its A.R.M.E.D ecosystem portfolio. Order intake accelerated in the second quarter to around €153 million, plus an additional €27 million in options, bringing year-to-date order intake to roughly €223 million with a further €68 million in options, figures that reflect the full consolidation of Kappa and Harder Digital order intake. THEON expects further acceleration in the second half of the year, mainly toward the end of the fourth quarter, and reiterated its guidance of maintaining an organic book-to-bill ratio above 1.0x for fiscal year 2026. The company also highlighted recent strategic moves, including a joint venture with Safran to enter drone technologies, in which THEON will hold a 51% stake with equal governance rights, and an initial agreement to acquire HGH Systèmes Infrarouges for an enterprise value of about €300 million, marking its entry into counter-drone systems.
About megatrends
Defense & Geopolitical Fragmentation › Soldier Systems & Protective Equipment ▲Demand
Defense & Geopolitical Fragmentation › Counter-UAS / Counter-Drone ▲Technology
Defense & Geopolitical Fragmentation › Autonomous Systems & Counter-Drone Technology
THEON.AS · Demand · Positive THEON receives ~€70M new orders, including from Rheinmetall for Bundeswehr program, and expects further acceleration.
RHM.XETRA · Demand · Positive Rheinmetall is the customer placing orders for the Bundeswehr program, indicating demand for its products.
SAF.PA · Technology · Positive Safran enters a joint venture with THEON to develop drone technologies, with equal governance rights.
HGH Systèmes Infrarouges · Technology · Positive THEON agrees to acquire HGH Systèmes Infrarouges for €300M, entering counter-drone systems.
Read original ↗
THEON International PLC·104dRead more →
Defense & Geopolitical Fragmentation▲

THEON enters exclusivity deal to acquire HGH for €300 million

THEON International Plc has entered into an exclusivity agreement with Carlyle to acquire SAS Stéropès, the holding company of HGH Systèmes Infrarouges, for an enterprise value of approximately €300 million. HGH designs and manufactures electro-optical and infrared systems for defense and civil applications, employs over 130 people, and generated around €40 million in revenue with an EBITDA margin above 40% and a roughly 30% compound annual growth rate since 2023. The acquisition is expected to be mid-single-digit earnings-per-share accretive in 2027 and will be financed through a bridge facility from BNP Paribas, with no equity capital increase planned. The deal, which remains subject to works council consultation and regulatory approvals, is anticipated to close by the fourth quarter of 2026 and would broaden THEON's multi-domain intelligence, surveillance, and reconnaissance portfolio and counter-drone solutions.
About megatrends
Defense & Geopolitical Fragmentation › Defense Electronics, EW & Sensors Competition
Defense & Geopolitical Fragmentation › Counter-UAS / Counter-Drone Competition
THEON.AS · Capital · Positive THEON enters exclusivity to acquire HGH for €300M, expected to be EPS accretive in 2027, broadening its portfolio.
HGH Systèmes Infrarouges · Capital · Positive HGH is the acquisition target; the deal values it at €300M, reflecting its strong growth and margins.
SAS Stéropès · Capital · Positive SAS Stéropès is the holding company being acquired; the deal implies a positive valuation for its shareholders.
Read original ↗
THEON International PLC·109dRead more →